TY - JOUR
T1 - Treatment of neurometabolic epilepsies
T2 - Overview and recent advances
AU - Tokatly Latzer, Itay
AU - Pearl, Phillip L.
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/5
Y1 - 2023/5
N2 - The rarity and heterogeneity of neurometabolic diseases make it challenging to reach evidence-based principles for their specific treatments. Indeed, current treatments for many of these diseases remain symptomatic and supportive. However, an ongoing scientific and medical revolution has led to dramatic breakthroughs in molecular sciences and genetics, revealing precise pathophysiologic mechanisms. Accordingly, this has led to significant progress in the development of novel therapeutic approaches aimed at treating epilepsy resulting from these conditions, as well as their other manifestations. We overview recent notable treatment advancements, from vitamins, trace minerals, and diets to unique medications targeting the elemental pathophysiology at a molecular or cellular level, including enzyme replacement therapy, enzyme enhancing therapy, antisense oligonucleotide therapy, stem cell transplantation, and gene therapy.
AB - The rarity and heterogeneity of neurometabolic diseases make it challenging to reach evidence-based principles for their specific treatments. Indeed, current treatments for many of these diseases remain symptomatic and supportive. However, an ongoing scientific and medical revolution has led to dramatic breakthroughs in molecular sciences and genetics, revealing precise pathophysiologic mechanisms. Accordingly, this has led to significant progress in the development of novel therapeutic approaches aimed at treating epilepsy resulting from these conditions, as well as their other manifestations. We overview recent notable treatment advancements, from vitamins, trace minerals, and diets to unique medications targeting the elemental pathophysiology at a molecular or cellular level, including enzyme replacement therapy, enzyme enhancing therapy, antisense oligonucleotide therapy, stem cell transplantation, and gene therapy.
KW - Inborn errors of metabolism
KW - Metabolic
KW - Progress
KW - Therapy
KW - Update
UR - http://www.scopus.com/inward/record.url?scp=85151379614&partnerID=8YFLogxK
U2 - 10.1016/j.yebeh.2023.109181
DO - 10.1016/j.yebeh.2023.109181
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 37001467
AN - SCOPUS:85151379614
SN - 1525-5050
VL - 142
JO - Epilepsy and Behavior
JF - Epilepsy and Behavior
M1 - 109181
ER -